 |
|
Where do new therapies work best?
June 23, 2006Anti-TNFS compared across rheumatic diseases show they may work better in some more than others
An observational study to investigate how new therapies for rheumatic diseases perform across different conditions has revealed that they may be more successful in certain conditions. The data is presented today at the Annual European Congress of Rheumatology in Amsterdam, the Netherlands. An increasing proportion of patients with rheumatic conditions such as ankylosing spondylitis (AS), psoriatic arthritis (PsA) and rheumatoid arthritis (RA) now receive anti-TNF treatment — a newer group of drugs which are used to reduce inflammation and manage disease activity*. Study lead Dr Marte Heiberg, of the Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, told delegates: "Many studies have focused on efficacy of these drugs, however less is known about comparative real life performance of these drugs across different diagnostic groups".
The study was conducted across 5 Norwegian Rheumatology Departments and included 796 RA patients, 162 PsA patients and 211 patients with a diagnosis of AS. All patients were on an anti-TNF treatment regimen of infliximab, etanercept or adalimumab +/- methotrexate (MTX). The primary outcome was the number of patients still on therapy at one year — known as the adherence to therapy. RA was used as the reference group and within each diagnostic group the adherence to anti-TNF monotherapy versus TNF+MTX was compared.
The relative risk for withdrawal from TNF+MTX versus anti-TNF monotherapy was 0.54 for RA patients, 0.49 for PsA patients and 0.83 for AS patients, demonstrating that combination treatment strategy of anti-TNF+MTX worked better than anti-TNF monotherapy in patients with RA and PsA. Although the crude one-year overall drug adherence rates for anti-TNF therapy were superior in patients with PsA and AS compared to RA, after adjusting for age, gender and concomitant MTX, the adherence to anti-TNF treatment were similar in patients with RA and PsA whereas the adherence to anti-TNF treatment was superior in patients with AS compared to RA.
Dr Heiberg stated: "This is a fresh insight into the performance of these very good treatment options and helps to build a greater picture of how they work across the different rheumatology disease areas. Whilst many of the anti-TNFs were originally used in RA, it is most interesting to note that they could actually work for a comparatively larger proportion of patients with an AS diagnosis."
European League Against Rheumatism
The relative risk for withdrawal from TNF+MTX versus anti-TNF monotherapy was 0.54 for RA patients, 0.49 for PsA patients and 0.83 for AS patients, demonstrating that combination treatment strategy of anti-TNF+MTX worked better than anti-TNF monotherapy in patients with RA and PsA. Although the crude one-year overall drug adherence rates for anti-TNF therapy were superior in patients with PsA and AS compared to RA, after adjusting for age, gender and concomitant MTX, the adherence to anti-TNF treatment were similar in patients with RA and PsA whereas the adherence to anti-TNF treatment was superior in patients with AS compared to RA.
Dr Heiberg stated: "This is a fresh insight into the performance of these very good treatment options and helps to build a greater picture of how they work across the different rheumatology disease areas. Whilst many of the anti-TNFs were originally used in RA, it is most interesting to note that they could actually work for a comparatively larger proportion of patients with an AS diagnosis."
European League Against Rheumatism
New Therapies Current Events and New Therapies News RSSNational Science Foundation congratulates Nobel Laureates in medicine/physiology, chemistry and economics
The National Science Foundation (NSF) congratulates the 2009 Nobel laureates, particularly those who have received NSF funding over the years: Jack W. Szostak, who shared the prize in physiology or medicine; Thomas A. Steitz, who shared the prize in chemistry; and Elinor Ostrom and Oliver E. Williamson who earned the Sveriges Riksbank Prize in economic sciences in memory of Alfred Nobel 2009.
Studying cancer in pet dogs to find new treatments for human patients
A team of scientists at the National Cancer Institute (NCI) in Bethesda, USA, says that studying pet dogs with cancer could yield valuable information on how to diagnose and treat human cancers.
More infants surviving pre-term births results in higher rates of eye problems
As more extremely pre-term infants survive in Sweden, an increasing number of babies are experiencing vision problems caused by abnormalities involving the retina.
Loss of tumor supressor gene essential to transforming benign nerve tumors into cancers
Researchers at UCLA's Jonsson Comprehensive Cancer Center showed for the first time that the loss or decreased expression of the tumor suppressor gene PTEN plays a central role in the malignant transformation of benign nerve tumors called neurofibromas into a malignant and extremely deadly form of sarcoma.
Governor recognizes stem cell research at Einstein
Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today.
New drug aims to 'seek and destroy' many types of cancer
A new drug designed to "seek and destroy" common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.
The vasculature emerges as a potential therapeutic target in treating ADPKD liver cysts
As part of an effort to develop effective medical therapies that block the progression of liver cyst growth in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD), researchers at the University of Colorado Anschutz Medical Center have found that the liver cyst walls develop and maintain a vasculature as they grow out from the body of the liver and that factors released by epithelial cells that line the liver cyst wall lumen can drive the proliferation and development of vascular endothelial cells.
Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award
A scientist at the La Jolla Institute for Allergy & Immunology has received one of the National Institutes of Health (NIH)'s top awards -- the 2009 NIH Director's Pioneer Award.
Mayo Clinic identifies 2 genes as potential therapeutic targets for multiple sclerosis
A Mayo Clinic study has found that two genes in mice were associated with good central nervous system repair in multiple sclerosis (MS).
Researchers restore missing protein in rare genetic brain disorder
UCSF researchers have successfully used protease inhibitors to restore to normal levels a key protein involved in early brain development. Reduced levels of that protein have been shown to cause the rare brain disorder lissencephaly, which is characterized by brain malformations, seizures, severe mental retardation and very early death in human infants.
More New Therapies Current Events and New Therapies News Articles
 |
Feeling Good: The New Mood Therapy Revised and Updated by David D. Burns (Author) FEELING GOOD FEELS WONDERFUL The good news is that anxiety, guilt, pessimism, procrastination, low self-esteem, and other "black holes" of depression can be cured without drugs.In FEELING GOOD, eminent psychiatrist, David D. Burns, M.D., outlines the remarkable, scientifically proven techniques that will immediately lift your spirits and help you develop a positive outlook on life. Now, in this updated edition, Dr. Burns adds an ALL-NEW CONSUMER'S GUIDE TO ANTIDEPRESSANT DRUGS as well as a new introduction to help answer your questions about the many options available for treating depression. - Recognize what causes your mood swings |
 |
Sweet Dreams Massage Therapy Music (Primary Contributor) |
 |
Beyond Therapy: A New Comedy by Christopher Durang Beyond Therapy (Performer) |
 |
New 6 mm Hematite Band Magnetic Therapy Ring Size 6 by Gem Avenue Magnetic Hematite Unisex Ring. This is a lovely ring and you will like it. We carry this ring in sizes 6 through 12. You will get the size you bid / buy. Size Changes cannot be done after the fact. |
 |
ABC News Primetime Art Therapy For a group of children who lost their fathers on September 11th, art therapy is playing an important role in overcoming profound sorrow. ABC News explores how children are often better able to express their pain, grief and fears through pictures rather than words. Correspondent: Jay Schadler ... |
 |
New Hot Cold Buckwheat Therapeutic Heat Therapy Bag Pad by BlockBusterClearance Wrap-around design helps keep heat or cold targeted where you need it! Never suffer through headaches, arthritis pains or other common ailments again without the therapeutic relief of these great hot & cold bags. Genuine buckwheat grains will remain at the desired temperature for up to 30 minutes - Accept no substitute! |
 |
Doctor Little Man Also With: Kari Lizer (Producer), Andy Ackerman (Producer) |
 |
New!! CND Creative Spa Spapedicure Cucumber Heel Therapy 15oz by Creative Nail Design Creative Spa SpaPedicure Cucumber Heel Therapy is a rich, restorative heel cream which contains a moisture intensive complex of aloe, allantoin, panthenol and urea to aid in the repair of dry, cracked skin. Relieves the effects of severe dryness on heels and other parts of the body. Daily use provides noticeable improvement in a short time. Concentrated formula can be used sparingly. |
 |
Talika Eye Therapy Patch Refill 6 ea by Talika America LLC reusable eye contour patch with essential oils and ceramide III clinically proven to reduce wrinkles after 1 use 6 pairs Spectacular reduction of undereye wrinkles in 30 minutes! Eye Therapy Patch is the first cosmetic application of a post surgery technological discovery offering exceptional characteristics and efficiency: controlled and progressive release of active ingredients re-use up to three times spectacular results The results are visible and have been proven by Dermatologists at the Hopitaux de Paris de la Salpetriere. After just one use: wrinkles are lessened dark circles and eye puffiness are reduced scars are diminished Made in France |
 |
Scar Fx Silicone Scar Therapy, Size Of Patch 1 1/2" X 9", 1 Patch by Rejuvaskin Scar Fx Silicone Sheeting is recommended by plastic surgeons, dermatologists and Gynecologist around the world. Scar Fx Silicone Sheet with a self adhesive side is medically proven in helping reduce the appearance, size, height, thickness, and color of scars for all skin types and color. Scar Fx works well on both new and old scars regardless of the age of the scar, and can be used on all types of post-surgery scars, hypertrophic and keloid scars, and other scar types caused by injury, trauma, and burns. Additionally, this silicone sheet may be used to help in the prevention of hypertrophic and keloid scarring when used on closed scars following surgery, trauma, or burns. This silicone sheet can be used for all types of surgical procedures. Scar Fx Silicone Sheet can be easily cut by... |
| © 2009 BrightSurf.com |